HK1213294A1 - 穩定的非多腺苷酸化 的產生 - Google Patents

穩定的非多腺苷酸化 的產生

Info

Publication number
HK1213294A1
HK1213294A1 HK16101305.0A HK16101305A HK1213294A1 HK 1213294 A1 HK1213294 A1 HK 1213294A1 HK 16101305 A HK16101305 A HK 16101305A HK 1213294 A1 HK1213294 A1 HK 1213294A1
Authority
HK
Hong Kong
Prior art keywords
production
stable non
polyadenylated rnas
rnas rna
rna
Prior art date
Application number
HK16101305.0A
Other languages
English (en)
Inventor
Jeremy E Wilusz
Phillip A Sharp
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of HK1213294A1 publication Critical patent/HK1213294A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
HK16101305.0A 2012-10-16 2016-02-04 穩定的非多腺苷酸化 的產生 HK1213294A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261714697P 2012-10-16 2012-10-16
US201261716764P 2012-10-22 2012-10-22
US201261739153P 2012-12-19 2012-12-19
PCT/US2013/065239 WO2014062801A1 (en) 2012-10-16 2013-10-16 Production of stable non-polyadenylated rnas

Publications (1)

Publication Number Publication Date
HK1213294A1 true HK1213294A1 (zh) 2016-06-30

Family

ID=50488728

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16101305.0A HK1213294A1 (zh) 2012-10-16 2016-02-04 穩定的非多腺苷酸化 的產生

Country Status (11)

Country Link
US (2) US9717749B2 (zh)
EP (1) EP2909321A4 (zh)
JP (1) JP2015536647A (zh)
KR (1) KR20150070307A (zh)
CN (1) CN104955951A (zh)
AU (1) AU2013331351A1 (zh)
CA (1) CA2888215A1 (zh)
HK (1) HK1213294A1 (zh)
IL (1) IL238256A0 (zh)
MX (1) MX2015004853A (zh)
WO (1) WO2014062801A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015004853A (es) 2012-10-16 2015-12-09 Massachusetts Inst Technology Produccion de acidos ribonucleicos no poliadenilados estables.
CA2964796C (en) * 2014-10-17 2022-01-11 The Penn State Research Foundation Methods and compositions for multiplex rna guided genome editing and other rna technologies
US12019066B2 (en) * 2016-05-16 2024-06-25 Biomadison, Inc. Assay with synaptobrevin based moiety
SG11201908043UA (en) * 2017-03-02 2019-09-27 Meiragtx Uk Ii Limited Regulation of gene expression by aptamer-modulated rnase p cleavage
US10378070B2 (en) * 2017-09-07 2019-08-13 Kyoto University Vector and gene introduction agent for monitoring and visualizing cell differentiation using expression of micro RNA as indicator and monitoring and visualizing method using thereof
CN112236153A (zh) 2018-04-05 2021-01-15 阿兹特拉公司 用重组微生物治疗皮肤疾病的方法和组合物
AU2020260154A1 (en) * 2019-04-17 2021-11-11 The Trustees Of The University Of Pennsylvania Triple helix terminator for efficient RNA trans-splicing
CN112790125B (zh) * 2021-01-22 2022-09-06 中国科学院水生生物研究所 一种玉兔百褶裙泰狮金鱼的创制方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824497A (en) * 1995-02-10 1998-10-20 Mcmaster University High efficiency translation of mRNA molecules
US6242187B1 (en) * 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
SG181564A1 (en) 2009-12-07 2012-07-30 Katalin Kariko Rna preparations comprising purified modified rna for reprogramming cells
US8853377B2 (en) 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
EP3460064B8 (en) * 2011-04-03 2024-03-20 The General Hospital Corporation d/b/a Massachusetts General Hospital Efficient protein expression in vivo using modified rna (mod-rna)
MX2015004853A (es) 2012-10-16 2015-12-09 Massachusetts Inst Technology Produccion de acidos ribonucleicos no poliadenilados estables.

Also Published As

Publication number Publication date
WO2014062801A1 (en) 2014-04-24
US20180140625A1 (en) 2018-05-24
US20150315574A1 (en) 2015-11-05
US10946035B2 (en) 2021-03-16
CA2888215A1 (en) 2014-04-24
EP2909321A4 (en) 2016-06-22
US9717749B2 (en) 2017-08-01
MX2015004853A (es) 2015-12-09
EP2909321A1 (en) 2015-08-26
JP2015536647A (ja) 2015-12-24
CN104955951A (zh) 2015-09-30
KR20150070307A (ko) 2015-06-24
AU2013331351A1 (en) 2015-04-30
IL238256A0 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
HK1243459A1 (zh) 從經基因改造的微生物生產黏康酸
HK1209340A1 (zh) 信使 的肺遞送
EP2971033B8 (en) Manufacturing methods for production of rna transcripts
ZA201307924B (en) Co-products from biofuel production processes and methods of making the same
GB201104096D0 (en) Production of graphene
SG11201405573WA (en) Production of graphene
EP2799548A4 (en) ANTISENSE NUCLEIC ACID
HK1213294A1 (zh) 穩定的非多腺苷酸化 的產生
SG10201602369PA (en) Double-Stranded RNA (dsRNA) For Inhibiting Expression Of TMPRSS6
SG11201500187WA (en) Methods of manufacturing cartilage products
EP2798063A4 (en) PREPARATION OF DIHYDROSTERCULINIC ACID AND DERIVATIVES THEREOF
EP2545183A4 (en) MONOCATERARY CIRCULAR NUCLEIC ACID PRODUCTION
HK1209621A1 (zh) 家族微小 的抑制劑
ZA201401948B (en) Improved nitric acid production
PL2537841T3 (pl) Ciągłe wytwarzanie furfuralu oraz kwasu lewulinowego
SG10201604562PA (en) Biotechnological production of 3-hydroxyisobutyric acid
HK1194105A1 (zh) 生物產品的單容器製造
PL2870188T3 (pl) Wytwarzanie tworzyw piankowych o ulepszonych właściwościach
GB201120696D0 (en) Production of mono-cystalline silicon
GB201004096D0 (en) Production of polyhydroalkanoates
GB201222832D0 (en) Manufacture of hollow parts
SG11201401898UA (en) Production of low cloud point distillates
GB201220155D0 (en) Method of manufacture
HK1203967A1 (zh) 神經節苷脂生產的方法
GB201117482D0 (en) Targetiing of miRNA precursors